ACADEMIA
TMDU Research Team Calls for New Hypothesis on Cause of AD; Could Lead to Development of Gene Therapy
Researchers of the Tokyo Medical and Dental University’s (TMDU) Medical Research Institute, proposed on January 24 a new hypothesis on the cause of Alzheimer’s disease (AD) that revises the conventional amyloid hypothesis. Under the conventional hypothesis, the amyloid β (Aβ)…
To read the full story
ACADEMIA
- Arava Safety Backup at Risk as Questran Supply Falters on Nitrosamine Issue
May 11, 2026
- NCC Launches First Japan Trial for CP Inhibitor-Related Liver Dysfunction
April 27, 2026
- Dementia Drugs See Modest Uptake in Japan amid Eligibility Limits, Safety Concerns
April 9, 2026
- Cancer Drug Supply Risks Spur Calls for Pricing Reform: JSMO
March 31, 2026
- Japan Ophthalmology Society Flags Off-Label Concerns Ahead of Upneeq Launch
March 30, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





